Despite ongoing research on this target, unintended side effects such as hyperglycaemia, rash, diarrhoea/colitis, hepatotoxicity and hypertension continue to be a major barrier to the development of PI3K inhibitors (Hanker et al. 2019). The gene discussed is PIK3CD; the disease is Hyperglycemia.